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Abstract
The Eap (extracellular adherence protein) of Staphylococcus aureus functions as a 
secreted virulence factor by mediating interactions between the bacterial cell surface and 
several extracellular host proteins. Eap proteins from different Staphylococcal strains 
consist of four to six tandem repeats of a structurally uncharacterized domain (EAP 
domain). We have determined the three-dimensional structures of three different EAP 
domains to 1.8, 2.2, and 1.35 Å resolution, respectively. These structures reveal a core 
fold that is comprised of an -helix lying diagonally across a five-stranded, mixed -
sheet. Comparison of EAP domains with known structures reveals an unexpected 
homologywith the C-terminal domain of bacterial superantigens. Examination of the 
structure of the superantigen SEC2 bound to the -chain of a T-cell receptor suggests a 
possible ligand-binding site within the EAP domain (Fields, B. A., Malchiodi, E. L., Li,
H., Ysern, X., Stauffacher, C. V., Schlievert, P. M., Karjalainen, K., and Mariuzza, R. 
(1996) Nature 384, 188–192). These results provide the first structural characterization of 
EAP domains, relate EAP domains to a large class of bacterial toxins, and will guide the 
design of future experiments to analyze EAP domain structure/function relationships.
Introduction
Staphylococcus aureus is a widespread, persistent pathogen that causes a broad range of 
diseases in humans and animals, from simple wound infections to more severe conditions 
such as septicemia, endocarditis, and osteomyelitis (2). As is the case with many
pathogens, initiation of S. aureus infection requires colonization of unique 
microenvironments within the host. To facilitate host colonization, S. aureus expresses a 
diverse array of virulence-determining factors, including exoenzymes, toxins, and 
numerous protein adhesins. These adhesins (termed Receptins (3, 4) or MSCRAMMs (4) 
(for microbial surface components recognizing adhesive matrix molecules)) are believed 
to contribute to the initiation and propagation of infections by precluding bacterial 
clearance by physical forces (e.g. blood flow, coughing, etc.) and providing protection 
against host immune responses (4).
Although different receptins bind a variety of ligands in host tissues, a common feature is 
their ability to bind specifically to the large glycoproteins present in the extracellular 
matrix (e.g. fibronectin, collagen, and fibrinogen) (reviewed in Ref. 5). The 50–70-kDa 
Eap (extracellular adherence protein) of S. aureus was originally identified based on its 
ability to bind glomerular basement membranes (6), and more mechanistic studies have 
demonstrated that Eap is capable of binding a wide array of extracellular matrix proteins 
(7–9), including fibronectin, vitronectin, laminin, and the pro-inflammatory cell surface 
receptor intercellular adhesion molecule 1 (ICAM-1) (10). Despite the fact that the 
mature Eap protein lacks a transmembrane region, 30% of the steady-state level of Eap 
was found associated with the bacterial cell surface (9). Further studies demonstrated that 
this association can occur through specific protein-protein interactions (11) and 
uncharacterized membrane structures (12) as well as through Eap multimerization (9). 
Because no other receptin has these properties, Eap is believed to serve a unique role in 
bacterial virulence by mediating interactions between abundant host ligands (e.g.
fibrinogen, fibronectin, and vitronectin) and the bacterial cell. These interactions result in 
bacterial agglutination within the host and are believed to contribute to S. aureus
pathogenesis (9, 13, 14). Consistent with this idea, S. aureus strains that fail to produce 
Eap exhibit markedly lower affinity for eukaryotic cells (12–14) and lack the ability to 
efficiently enter and colonize nonphagocytic host cells (13, 14). Thus, there is interest in 
understanding and evaluating Eap-mediated interactions as potential targets for novel 
antimicrobial therapies (5).
Like many extracellular proteins, Eap exhibits a modular architecture and is believed to 
be comprised of tandem repeats of an 110-residue domain (EAP domain) (15, 16). 
Depending on the strain examined, Eap is comprised of either four or six repeats of this 
domain, although extensive homology between these isoforms and nearly
indistinguishable biochemical properties suggest that these proteins serve essentially the 
same physiological function (10, 17). These observations, combined with the wide variety 
of Eap ligands, imply that the individual EAP domains themselves are remarkably 
versatile in their ability to form protein-protein interactions. However, the biochemical 
properties of these domains are not well studied, nor do EAP domains share detectable 
sequence homology with any proteins of known structure.
As a first step toward a molecular understanding of EAP domain-mediated protein-
protein interactions, we determined the three-dimensional structures of three distinct EAP 
domain proteins to 1.8, 2.2, and 1.35 Å resolution, respectively. These structures consist 
of a 97-residue core fold composed primarily of a long -helix laying diagonally across a 
five-stranded, mixed -sheet. Comparison of EAP domains with other structures in the 
Protein Data Bank revealed an unexpected structural homology with the C-terminal 
domain of bacterial superantigens, a class of toxic proteins capable of massive stimulation 
of host lymphocytes by simultaneously binding both major histocompatibility class II 
proteins and T-cell receptors (TCRs)1 (18, 19). Examination of the crystal structure of the 
superantigen SEC bound to a TCR -chain suggests a potential ligand-binding site within 
the EAP domain (1). Our results provide the first insights into the structure of EAP 
domains and identify a novel and unexpected relationship between two broad classes of 
bacterial virulence factors. These results provide a framework for future studies
addressing the structure/function relationships of these and other EAP domain proteins.
Experimental procedures
Molecular Cloning and Sequence Analysis
S. aureus strain Mu50 was purchased from ATCC and subcultured in liquid LB medium 
using standard techniques. Genomic DNA was isolated from 1 liter of stationary phase 
bacteria according to the procedure originally described by Marmur (20), with the
exception that lysostaphin (Sigma) was included in the lysis buffer according to the 
manufacturer's suggestions. The crude preparation of genomic DNA was purified further 
by standard extraction and precipitation techniques and resuspended in double distilled 
H2O to a final concentration of 1.0 mg/ml (A260/A280 = 1.7).
The genes encoding EapH1 (GenBankTM accession number NP_372729) and EapH2 
(GenBankTM accession number NP_371505) were identified in the Mu50 genomic 
sequence by BLAST searching with entire amino acid sequence of Eap (GenBankTM
accession number NP_372462). The conceptual translation of each gene was analyzed for 
the highest probability signal peptide cleavage site using the SignalP algorithm Gram-
positive option (www.cbs.dtu.dk/services/SignalP/). DNAs encoding residues 31–141 of 
EapH1, residues 24–144 of EapH2, and residues 160–254 of Eap (the second EAP repeat, 
denoted EAP2) were amplified by PCR from Mu50 genomic DNA with SalI and NotI 
restriction endonuclease recognition sites at the 5' and 3' ends, respectively, subcloned 
into the corresponding sites of the pT7HMT Escherichia coli expression vector,2 and 
sequenced in their entirety.
Site-directed mutagenesis was used to insert additional methionine residues in the EapH1 
protein to facilitate phasing by multiwavelength anomalous dispersion (MAD) (22). The 
codons for Val91, Ile96, Leu106, and Val116 were mutated independently to encode 
methionine by a two-step, megaprimer method to create four independent proteins with 
single-site methionine substitutions (23). Mutant DNAs encoding each variant protein 
were subcloned into pT7HMT and sequenced in their entirety. All of the sequence 
alignments were performed using the DNASTAR software suite.
Protein Overexpression and Purification
E. coli strain B834(DE3) was used for overexpression of all proteins. Cell growth for the 
production of native proteins was carried out at 37 °C as previously described (24). 
Following induction, the cells were harvested by centrifugation, resuspended in 50 ml of 
denaturing lysis buffer (0.1 M sodium Pi (7.8), 6 M guanidinium HCl) per liter of original 
culture, lysed by stirring for 30 min at room temperature, and the solubilized, denatured 
proteins were separated from cellular debris by centrifugation (30 min at 30,000 x g). The 
clarified cell extract was applied by gravity flow to a 7.5-ml column of Ni2+-
nitrilotriacetic acid-Sepharose (Qiagen) at room temperature, and His-tagged proteins 
were isolated according to manufacturer's suggestions. Following purification, 
recombinant proteins were refolded by rapid dilution2 and concentrated by native 
chelating chromatography according to the manufacturer's suggestions (Qiagen).
The purified EAP domain fusion proteins were digested with recombinant TEV protease 
(Invitrogen) at 4 °C according to the manufacturer's suggestions) to avoid potential 
crystallization problems caused by the presence of the N-terminal fusion tag. When 
digestion was complete (as judged by SDS-PAGE), the samples were exchanged into 20 
mM sodium formate (pH 3.5), applied to a 6-ml Resource S cation exchange column 
(Amersham Biosciences), washed free of loosely bound contaminants, and eluted with a 
gradient from 0 to 1 M NaCl over 10 column volumes. Fractions containing apparently
homogenous EapH1, EapH2, or EAP2 were pooled, dialyzed once overnight against 4 
liters of double distilled H2O using a 3500 molecular weight cut-off Slidealyzer cassette 
(Pierce Biotechnology), and lyophilized for storage.
For overexpression of selenomethionyl-derivatized mutant proteins, selective M9 
minimal medium containing 50 mg/liter of seleno-L-methionine (Sigma) was prepared 
and used according to the general procedure of Beneken et al. (25). Each derivatized 
protein was purified from the cells in 1 liter of induced culture according to the same 
protocol used for native proteins, with the exception that all of the buffers were vacuum-
degassed prior to use. The incorporation of selenomethionine in each mutant was 
complete as judged by matrix-assisted laser desorption ionization time-of-flight mass
spectrometry (PerkinElmer Life Sciences).
Crystallization and Data Collection
All of the crystals were grown in hanging drops at 20 °C by mixing 1 µl of protein 
solution (in water) with 1 µl of a 1:3 dilution of reservoir buffer in water and equilibrating
over 750 µl of undiluted reservoir buffer. The crystals used for diffraction analysis were 
soaked briefly in a fresh aliquot of reservoir buffer and flash frozen in a gaseous nitrogen
stream at –180 °C prior to data collection. All of the data were processed and scaled using 
the DENZO/SCALEPACK software suite (26). The data collection statistics are shown in 
Tables II and III. The crystallization conditions and related information for each protein is 
presented below.
TABLE II
Data collection for experimental MAD phasing and structure solution
The values in parentheses are for the highest resolution shell.
TABLE III
Data collection for model building and refinement
The values in parentheses are for the highest resolution shell.
EapH1—30 mg/ml protein was mixed with a reservoir buffer of 0.1 M sodium cacodylate 
(pH 6.7), 0.2 M zinc acetate, and 24% (w/v) polyethylene glycol 8000. Twinned, needle-
like crystals appeared in 3–4 days and continued to grow through 14 days. Diffraction 
quality crystals were grown by microseeding fragments of the needle crystals into 
identical drops that had been pre-equilibrated for 12 h. EapH1 crystals suitable for
diffraction analysis grew in the space group P32 (unit cell dimensions: a = b = 38.55 Å, c
= 69.23 Å). The diffraction data for MAD phasing were collected at Selenium edge, peak,
and remote wavelengths for crystals of the I96M and L106M mutants using Beamline 
X4A of the National Synchrotron Light Source at Brookhaven National Laboratory. The 
diffraction data used for high resolution refinement were collected at Beamline 14BM-C
of the Advanced Photon Source at Argonne National Laboratory.
EapH2—30 mg/ml protein was mixed with a reservoir buffer of 0.1 M sodium cacodylate 
(pH 6.7), 0.2 M ammonium acetate, 30% (w/v) polyethylene glycol 8000, and 4% (w/v) 
2,6-hexanediol. Twinned, needle-like crystals appeared within 2 days and achieved their 
full size in approximately 1 week. Microseeding produced a single crystal that grew in the 
space group P21 (unit cell dimensions: a = 50.01 Å, b = 31.97 Å, c = 67.98 Å; = 
105.21°) and contained two molecules in the asymmetric unit. The diffraction data were 
collected using CuK radiation produced by a Rigaku RU-200 generator.
EAP2—13 mg/ml protein was mixed with a reservoir buffer of 0.1 M MES (pH 6.4), 0.1 M
ammonium sulfate, and 24% (w/v) polyethylene glycol 8000. Single crystals appeared 
within 1 day, achieved their full size in approximately 1 week, and grew in the space 
group R3 (unit cell dimensions: a = b = 64.116 Å, c = 141.706 Å) with two molecules in 
the asymmetric unit. The diffraction data were collected at Beamline X4A of the National 
Synchrotron Light Source.
Structure Solution and Refinement
The two anticipated selenium sites in both the I96M and L106M mutants of EapH1 (one 
native and one introduced) were determined and the phases calculated using the program 
SOLVE (27). To generate the final experimental phases, complete, three wavelength 
MAD data sets from both mutants were combined into a single, pseudo-multiple
isomorphous replacement data set. The experimental values for the Figure of merit ( m ) 
are shown in Tables II and III. After the experimental phases were improved by solvent 
flattening and histogram matching protocols (RESOLVE) (28, 29), an initial model of 
residues 45–141 was built into 2.2 Å experimental electron density maps using the 
program O (30). The model was subjected to a single round of simulated annealing and 
maximum-likelihood positional refinement using CNS and a native data set processed to 
1.8 Å limiting resolution (31). Iterative rounds of model building and water addition were 
alternated with B-factor and positional refinement to yield the final model. This model
consists of residues 43–141, 95 water molecules, and two ordered zinc ions. No electron 
density was observed for residues 31–42. The final model was analyzed by the program 
PROCHECK in CCP4 (32, 33). Greater than 90% of the residues were found in the most 
favorable regions of the Ramachandran plot, and no residues were found in the 
disallowed regions. The final refinement statistics are shown in Tables II and III.
The structure of EapH2 was solved by molecular replacement using the program 
MOLREP and the refined structure of EapH1 as a search model (32, 34). The top two 
molecular replacement solutions yielded models for both EapH2 molecules in the 
asymmetric unit, which were then subjected to a single round of simulated annealing prior 
to building a 2.2 Å limiting resolution initial model of residues 45–144 in both 
polypeptide chains using the program O (30). Several rounds of model rebuilding and 
water addition, alternated with positional and individual B-factor refinement, yielded the 
final model. This model consists of residues 42–144 for the first protein molecule in the
asymmetric unit, residues 45–144 for the second protein molecule, and 76 ordered solvent 
molecules. Superposition of all of the C positions of these polypeptide chains revealed
no significant structural differences between the two molecules (r.m.s.d. = 0.43 Å). The 
orientation of the noncrystallographic symmetry axis is not likely to reflect any 
physiologically relevant dimerization because the EapH2 protein behaves as a monomer
in solution at concentrations up to 2 mM as judged by analytical size exclusion 
chromatography (data not shown). The final model was analyzed by the program 
PROCHECK (32, 33). Greater than 90% of the residues were found in the most favorable 
regions of the Ramachandran plot, and no residues were found in the disallowed regions. 
The final refinement statistics are shown in Tables II and III.
The structure of EAP2 was solved by molecular replacement using the CCP4 program 
MOLREP and a single molecule from the refined structure of EapH2 as a search model 
(32, 34). The top molecular replacement solutions yielded models for both EAP2 
molecules in the asymmetric unit, which were subjected to a single round of rigid body 
refinement and simulated annealing prior to building a 1.35 Å limiting resolution initial 
model of residues 160–254 in both polypeptide chains using the program O (30). 
Noncrystallographic symmetry constraints were applied during the early stages of 
refinement and were removed once the Rfree value dropped below 40%. Several additional 
rounds of model rebuilding and water addition, alternated with positional and individual 
B-factor refinement, yielded the final model. This model consists of residues 160–254 for 
both protein molecules in the asymmetric unit, in addition to the residues Gly-Ser-Thr (an 
artifact of subcloning) at the N terminus, and 304 ordered solvent molecules. 
Superposition of all C positions from both polypeptide chains revealed no significant 
structuraldifferences between the two molecules (r.m.s.d. = 0.29 Å). Again, the 
orientation of the noncrystallographic symmetry axis is unlikely to reflect any 
physiologically relevant dimerization because the EAP2 protein behaves as a monomer in 
solution at concentrations up to 2 mM as judged by analytical size exclusion
chromatography (data not shown). The final model was analyzed by the program 
PROCHECK (32, 33). Greater than 95% of the residues were found in the most favorable 
regions of the Ramachandran plot, and no residues were found in the disallowed regions.
The final refinement statistics are shown in Tables II and III.
Results
The Three-dimensional Structures of Three EAP Domains— Two uncharacterized EAP 
domain proteins were identified fromS. aureus strain Mu50 by a BLAST search of the 
nonredundant protein data base for small proteins that contain EAP domains. These 
proteins, denoted EapH1 (GenBankTM accession number NP_372729) and EapH2 
(GenBankTM accession number NP_37505), each contain a signal peptide at their N 
terminus, followed by a unique stretch of 10–20 residues and then a single EAP domain. 
EapH1 and EapH2 share 47% identity with one another and are 35 and 42% identical to 
the second repeat in the Eap protein (EAP2), respectively (Table I). DNAs encoding the 
predicted mature forms of each protein, as well as EAP2, were amplified from bacterial
genomic DNA, subcloned, and expressed in E. coli. Following purification, EapH1, 
EapH2, and EAP2 were crystallized by hanging drop vapor diffusion methods (see 
"Experimental Procedures").
TABLE I
Sequence similarities between the novel proteins EapH1 and EapH2 and the four 
subdomains of the Eap protein from Staphylococcus aureus Mu50
Sequences were aligned using the DNASTAR software suite and the percentage of 
sequence identity (top) and similarity (bottom) between the domains is presented. 
Similarity is defined as the percentage of identity plus the percentage of generally 
accepted conservative substitutions (e.g. Lys to Arg, Glu to Asp, etc.). The dashes 
indicate where values are not applicable.
The three-dimensional structure of EapH1 was determined using MAD data collected 
from crystals of selenomethionyl-substituted protein and refined to 1.8 Å limiting 
resolution (Fig. 1A and Tables II and III). The refined structure of EapH1 was used as a 
molecular replacement search model to determine the structure of EapH2, which was 
refined to 2.2 Å resolution (Fig. 1B and Tables II and III) and itself used as a molecular
replacement search model to determine the structure of EAP2 to 1.35 Å resolution (Fig. 
1C and Tables II and III). The EAP domain structures consist primarily of a fourturn -
helix laying diagonally across one face of a five-stranded, mixed -sheet and resemble an 
open hand holding a roll of coins (Fig. 1, rotated).
FIG. 1.
The crystal structures of EapH1, EapH2, and EAP2. The crystal structures of EapH1 
(A), EapH2 (B), and EAP2 (C) were solved and refined to 1.8, 2.2, and 1.35 Å limiting 
resolution, respectively. An alternative view of each structure achieved by rotating 90° 
counterclockwise in the viewing plane is shown on the right. Areas of distinct secondary 
structure were assigned by DSSP (21) and are colored green ( -helix), blue ( -sheet), and 
purple (310-helix). The two ordered zinc ions in the EapH1 structure (A) are represented 
by orange spheres. The protein termini are labeled accordingly.
Whereas the structures of all three EAP domains superimpose well (Table IV), two 
regions on either edge of the -sheet exhibit notable structural divergence between these 
proteins (Fig. 2). The first of these regions lies between the 1 and 2 strands. In the case 
of EapH1 and EapH2, a short, additional strand (denoted 1' in Fig. 1, A and B) is found; 
this element is absent from EAP2, although strand 2 is extended by two residues toward
the N terminus in this protein. The second and more significant region of structural 
divergence is found between strands 5 and 6. In case of EapH1 and EapH2, the 5– 6 
region consists of an ordered loop that contains a single turn of 310-helix (Fig. 1). This 
element is positioned roughly in the middle of the loop in EapH1 (Fig. 1A) but 
immediately follows strand 5 in EapH2 (Fig. 1B). This type of helical turn is not present
in the structure of EAP2 (Fig. 1C). In addition to adopting distinct structures, the residues 
comprising these regions generally exhibit more flexibility as evidenced by above 
average temperature factors when compared with the remainder of each molecule. In the 
case of 1 2, these values are 39.9, 39.6, and 30.2 Å2, whereas for 5 6 they are 40.7, 
31.1, and 20.6 Å2, where the mean temperature factors for the protein atoms are 30.2,
30.9, and 14.3 Å2 for the EapH1, EapH2, and EAP2 structures, respectively.
TABLE IV
Local-global alignment parameters for EapH1, EapH2, EAP2, and the superantigen 
TSST-1
The structures were subjected to local-global alignment (52) to quantitatively assess the 
C superpositions of the EAP domain(s) and TSST-1 structures. NS, number of residues 
in the refined structure; NT, number of residues in the reference structure; N, number of 
residues that superimpose within 2.5 Å; r.m.s.d.-N, root mean square deviation of N 
residues that fall within 2.5 Å.
FIG. 2.
Least squares superposition of EapH1, EapH2, and EAP2 reveals regions of 
structural divergence. The C backbone traces of EapH1 (blue), EapH2 (green), and 
EAP2 (purple) were superimposed by least squares fitting using the program O (30) and 
presented at both 0 (A) and 90° (B) views as in Fig. 1. The main regions of divergence 
between these structures occur in the loops between strands 1 2 and 5 6.
EAP Domains Share Unexpected Structural Homology with Bacterial Superantigens—
The EAP domain structures were compared with structures in the Protein Data Bank by 
using the structural alignment algorithm DALI (35). Surprisingly, this revealed that EAP 
domains share significant structural homology with the secreted pyrogenic superantigen 
toxins TSST-1 (Protein Data Bank code 1AW7  (36); Z = 10.7), and SEB (Protein Data 
Bank code 3SEB (37); Z = 8.2), both from S. aureus, and SPE-C (Protein Data Bank code 
1AN8  (38); Z = 9.1) from Streptococcus pyogenes. Members of the superantigen family 
of proteins are composed of two structurally distinct domains of approximately equal size 
(39). The N-terminal domain consists primarily of a -barrel structure that is similar to 
oligosaccharide/oligonucleotide-binding proteins (oligosaccharide-binding fold), whereas 
the C-terminal domain adopts a -grasp motif that is structurally homologous to EAP 
domains (Fig. 3A) (39). When comparing the EAP2 and TSST-1 C-terminal domains, 76 
of 98 C atoms superimpose within 2.5 Å distance and with an r.m.s.d. of 1.45 Å (Fig. 3, 
B and C, and Table IV). This level of structural similarity is surprisingly high because a 
relationship between these classes of proteins cannot be detected by PSI-BLAST.
FIG. 3.
EAP domains share unexpected structural homology to the C-terminal domain of 
bacterial superantigens. The structures of EapH1, EapH2, and EAP2 were analyzed for 
unexpected structural homology with structures deposited in the Protein Data Bank using 
the program DALI (35) (see "Results" and "Discussion"). A, a representative structure of 
the closest homolog, TSST-1 from S. aureus, is shown (36). The N-terminal, 
oligonucleotide/oligosaccharide-binding domain is depicted in gray scale, whereas the 
EAP-like domain is displayed in color as above. B and C, the C backbone traces of 
EAP2 (purple) and the EAP-like domain from TSST-1 (green) were superimposed by 
least squares fitting using the program O (30) and presented at both 0 (B) and 90° (C) 
views as in Figs. 1 and 2. The protein termini are labeled accordingly. D, the sequences 
of the EAP-like, C-terminal domains from several superantigens were aligned with those 
of selected EAP domains using the DNASTAR program suite. Areas of conserved 
secondary structure are colored green ( -helix), blue ( -sheet), and purple (310 -helix) and 
shown above the appropriate residues. The 5 6-interstrand region, which is the main site 
of sequence and structural variation within this protein family, is denoted with a dashed 
red line. Zinc-coordinating residues in EapH1 are marked with colored diamonds, with 
the residues comprising site 1 in green and site 2 in blue. Side chains donated by 
symmetry related molecules are depicted as clear diamonds.
Comparison of these two protein structures revealed again that two major regions of 
structural divergence lay within the 1 2 and 5 6 linker regions. Of these, the most 
striking difference is found between the 5 6 regions, where a longer 5 strand and more 
protruding loop conformation is seen in TSST-1CTD than in either EapH1, EapH2, or 
EAP2. Consistent with this observation, structure-based sequence alignment of several 
superantigen C-terminal domains with a group of EAP domains revealed that the 5 6 
linker region is the major site of sequence variation between these classes of proteins 
(Fig. 3D). In fact, with the exception of TSST-1, each superantigen examined contains an 
insertion of at least 13 residues in this region relative to EAP domains. This region is 
involved in mediating interactions between the superantigen SEC2 and the T-cell 
receptor, supporting the idea that this variable region can be exploited to confer different
binding specificities to EAP domains (Fig. 4).
FIG. 4.
Structural analysis of superantigen complexes implicates the 5 6-interstrand region as a 
main determinant of specificity in EAP domain-mediated protein-protein interactions. 
The structure of superantigen SEC2 complexed with the -chain of a mammalian T-cell 
receptor (TCR- ) is shown (1). The TCR molecule is drawn in lavender, whereas the 
EAP-like C-terminal domain is colored according to secondary structure elements. The 
N-terminal domain of SEC is omitted for clarity.
Discussion
To further our understanding of EAP domain structure and function, we have determined 
the crystal structures of three EAP domains, including the second repeat from S. aureus
Eap. The results presented here represent the first structural characterization of EAP 
repeat proteins and show that these domains adopt a -grasp fold composed of 97 
residues. This fold is shared by the C-terminal domains of bacterial superantigens and 
establishes the unexpected result that superantigens and EAP domain proteins are 
members of a diverse superfamily of secreted bacterial toxins and virulence factors. An 
attractive explanation for this structural and functional relationship is that EAP domains 
are a modular scaffold ideally suited to the formation of a wide variety of protein-protein
interactions. Consistent with this hypothesis, the structural classification of proteins 
(SCOP) database indicates that the ability to participate in protein-protein interactions is a
general feature of -grasp proteins (40) (scop.bic.nus.edu.sg/data/scop.b.e.bi.html).
Functionally characterized Eap proteins are composed of multiple copies of the EAP 
domain, although it is not known whether these domains interact with one another or 
behave as physically discrete modules. Primary sequence analysis, biochemical data, and 
the structures presented here support the latter model, however. First, the individual 
domains in Eap are separated by positively charged, 10–14-amino acid stretches that are 
predicted to be random coil by secondary structure prediction algorithms (e.g. Ph.D. (41) 
or PSI-PRED (42)). Second, the full-length Eap protein is sensitive to protease treatment 
and is readily digested into soluble, protease-stable fragments corresponding to individual 
EAP domains. This suggests that these linker residues are solvent-exposed and/or -
accessible. Finally, EAP domains assume a fold where the N- and C-terminal residues are
located at the opposite sides of the molecule. This topology is ideally suited to linking 
modular domains in succession and facilitates the formation of extended, rodlike 
structures. Similar arrangements are seen for fibronectin type III repeats and 
immunoglobulin domains, which are commonly found in extended arrays (43). This
topology, along with the points mentioned above, suggests that individual EAP domains 
are unlikely to interact with one another in an intramolecular fashion and that each 
domain acts a distinct binding module to create polyvalent EAP proteins capable of
interacting with a wide variety of ligands and surfaces simultaneously. This secreted, 
molecular "Velcro" could serve to concentrate regions of bacterial growth and ultimately 
promote the infection of host cell layers. In this respect, one lingering question is whether 
the individual domains in Eap are responsible for binding to specific ligands or, 
alternatively, if individual domains are capable of binding a diverse set of ligands.
The homology between EAP domains and the C-terminal domain of bacterial 
superantigens suggests that the 5 6-interstrand region may be an important determinant 
of the specificity of EAP domain-mediated protein-protein interactions, and there are 
several lines of evidence that support this hypothesis. First, the crystal structure of 
superantigen SEC2 bound to a TCR -chain revealed that residues lying within the 5 6-
interstrand region are critical in forming this complex (1). Second, residues affecting the 
TCR -chain binding specificity of superantigen SEA are found in the N-terminal portion 
of this region (44). Finally, examination of mutagenesis data in light of the TSST-1 
crystal structure has implicated residues within the 5 6-interstrand region in toxin 
function (45). During the course of the studies presented here, we observed that the 5 6-
interstrand region is the main area of sequence and structural divergence within this 
family of secreted virulence factors and toxins. This suggests that the 5 6-interstrand 
region is able accommodate a variety of amino acid sequences and structures to form a 
potentially broad repertoire of ligand-binding sites. The high resolution structures of the 
EAP domains reported here serve as a foundation for future experiments to address this
question directly.
During the original characterization of S. aureus Eap, Jonsson et al. (15) reported that the 
individual EAP subdomains share a short region of homology with the N-terminal region 
of the -subunit of the major histocompatibility class II proteins. Specifically, residues 3–
33 in the mature major histocompatibility class II protein chain were found to be 
homologous to residues corresponding to positions 93–123, 101–131, and 206–236 in the 
mature forms of EapH1, EapH2, and Eap, respectively. However, this region of 
homology is not detectable by PSI-BLAST when a single EAP domain is used as a search 
query. To test whether the similarity between these regions was structurally significant, 
the C atoms of the residues in question from the major histocompatibility class II protein 
molecule (HLA-DR1) were superimposed upon the corresponding residues of the EAP
domains. This alignment revealed that the central region of the polypeptide chains were 
highly similar, both of which are comprised of two anti-parallel -strands joined by a 
short turn to form a -hairpin structure. The remainder of the polypeptide chains share 
little similarity, however, and the calculated r.m.s.d. of the C superposition in each case 
is greater than 7.21 Å. This strictly confined region of weak structural similarity is 
insufficient to support a conclusion of a divergent evolutionary relationship and suggests 
that any resemblance is incidental.
While solving the EapH1 structure, two unexpected peaks of high electron density were 
observed at the contacts between neighboring molecules in the crystal lattice. Several 
lines of evidence, including the bond lengths, tetrahedral geometry, coordinating residues, 
and presence of zinc ions in the crystallization buffer, suggested that these sites 
represented structural zinc ions (Fig. 1A). Both heavy atom sites appear well ordered in 
the final EapH1 model (BZn-1 = 27.8 Å2, BZn-2 = 42.3 Å2, where Bstructure = 32.2 Å2), a 
result that is consistent with the correct identification of these metal sites.
Zinc ions are have been shown to mediate the formation of superantigen complexes in 
both crystal lattices and solution, and zinc appears to be required for the biological 
activity of these toxins (39, 46–49). Despite the many similarities between superantigens
and EAP domains, zinc does not appear to be serving a conserved physiological role in 
EAP domain function. First, the zinc-coordinating residues in the EapH1 structure are not 
conserved in any other of the EAP domains examined (Fig. 3D). Not surprisingly, 
structural zinc ions were not observed in the EapH2 or EAP2 structure, nor were divalent 
cations required for crystallization of either of these proteins. Second, although each 
molecule of EapH1 binds two zinc ions in the structure, EapH1 does not exhibit metal-
dependent multimerization under physiologically relevant zinc concentrations ([Zn2+] 1 
mM; data not shown). Finally, no reports describe a requirement for zinc or other divalent 
cations in EAP domain structure or function. Thus, although it appears that metal binding 
is not a conserved feature of EAP domains, the possibility that divalent cations might 
contribute to the biochemical properties of specific EAP domain proteins, such as EapH1, 
cannot be ruled out at this time.
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